LONDON (Reuters) -Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...

Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...

Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...

The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...

The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23, 2023 ...

Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...

The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.

Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...

A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...

T he new weight-loss drugs Wegovy and Zepbound are in high demand, and the clamoring will only increase in coming years, ...